Senti Biosciences (NASDAQ: SNTI) — Perfil da empresa, notícias e dados financeiros
Senti Biosciences is a biotech company developing programmable biology therapies, primarily in oncology, using synthetic biology.
Senti Biosciences
Senti Biosciences (NASDAQ:SNTI) is a biotechnology company focused on developing programmable biology therapies. Leveraging advances in synthetic biology, Senti Biosciences aims to engineer smarter medicines that can outmaneuver complex diseases, with a particular emphasis on oncology. Their projects include designing cell and gene therapies that promise more precise, potent, and durable treatments for various cancers. The company's objectives center around accelerating the discovery and development of these innovative therapies, striving to transform how chronic diseases are treated. Senti Biosciences is dedicated to pushing the boundaries of medicine to improve patient outcomes and quality of life.
Resumo
Operações
Produtos e/ou serviços de Senti Biosciences
- Development of next-generation CAR-NK cell therapies for treating solid tumors, utilizing synthetic biology to enhance efficiency and targeting.
- Design of programmable cell therapies for oncological applications, focusing on improved selectivity and reduced toxicity.
- Research into logic-gated CAR-T cell therapies to increase precision and minimize off-target effects in cancer treatment.
- Creation of a proprietary platform for the rapid design, testing, and production of synthetic gene circuits for use in cell and gene therapies.
- Advancement of biosensors and diagnostic tools for real-time monitoring of cellular functions and therapy outcomes.
- Exploration of novel delivery methods for gene therapies to improve access to difficult-to-reach tissues and tumors.
equipe executiva do Senti Biosciences
- Timothy K. LuCo-Founder, CEO & Director
- Kanya RajangamPresident, Head of Research & Development and Chief Medical Officer
- James J. CollinsScientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
- Jay CrossChief Financial Officer
- Faraz SiddiquiSenior Vice President of Technical Operations
- Robert H. CutlerSenior VP & Head of Legal Affairs
- Thomas P. ChungVice President of Strategic Finance & Corporate Development
Principais indicadores financeiros
Resultados divulgados pela Senti Biosciences, em USD.
- Cap. de mercado
- 7,2 mi
- Receita (TTM)
- 55 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 22 mil | -63,7 mi | -61,4 mi | |
| 0 | -61 mi | -52,8 mi | |
| 2 mi | -92,7 mi | -71,1 mi | |
| 4,3 mi | -70,6 mi | -45,8 mi |